Eisai Co., Ltd.

This early-phase study tests a new drug called E7090, alone or with other cancer medicines, in people with a common type of advanced breast cancer (ER+, HER2-). The main goal is to find safe doses and understand side effects. About 51 participants will take part to guide future r…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This study tests a new drug combination (E7389 liposomal formulation plus nivolumab) in 125 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study is for people …

This study monitors the safety of the drug tazemetostat in 145 people with a type of lymphoma (follicular lymphoma) that has come back or not responded to treatment and has a specific gene change (EZH2 mutation). Researchers are tracking side effects and serious reactions during …